These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 16465140)

  • 1. Amgen becomes a stronger cancer player.
    Kling J
    Nat Biotechnol; 2006 Feb; 24(2):119. PubMed ID: 16465140
    [No Abstract]   [Full Text] [Related]  

  • 2. Deal watch: Bristol-Myers Squibb and Exelixis collaborate on kinase inhibitors.
    Nat Rev Drug Discov; 2009 Feb; 8(2):98. PubMed ID: 19180098
    [No Abstract]   [Full Text] [Related]  

  • 3. The closure of Sugen.
    Levitzki A
    Nat Biotechnol; 2003 Sep; 21(9):969. PubMed ID: 12949548
    [No Abstract]   [Full Text] [Related]  

  • 4. Closing in on cancer.
    O'Keefe B
    Fortune; 2001 Sep; 144(5):222. PubMed ID: 11559975
    [No Abstract]   [Full Text] [Related]  

  • 5. Cancer drugs that work.
    Hecht A
    FDA Consum; 1977 Oct; 11(8):18-21. PubMed ID: 10305002
    [No Abstract]   [Full Text] [Related]  

  • 6. Oncologic Drugs Advisory Committee and conflicts of interest.
    Burki TK
    Lancet Oncol; 2016 Mar; 17(3):e95. PubMed ID: 26877161
    [No Abstract]   [Full Text] [Related]  

  • 7. The second wave in kinase cancer drugs.
    Garber K
    Nat Biotechnol; 2006 Feb; 24(2):127-30. PubMed ID: 16465146
    [No Abstract]   [Full Text] [Related]  

  • 8. Sugen falls as casualty of Pfizer-Pharmacia merger.
    Garber K
    Nat Biotechnol; 2003 Jul; 21(7):722-3. PubMed ID: 12833079
    [No Abstract]   [Full Text] [Related]  

  • 9. A very firm handshake: biotech's growing negotiating power.
    Thiel KA
    Nat Biotechnol; 2005 Oct; 23(10):1221-6. PubMed ID: 16211058
    [No Abstract]   [Full Text] [Related]  

  • 10. Glyn Edwards talks about cancer drug development at Antisoma. Interview by Ulrike Knies-Bamforth and Dan Huke.
    Edwards G
    Drug Discov Today; 2005 Nov; 10(22):1491-4. PubMed ID: 16257369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pfizer jettisons Esperion.
    Shaffer C
    Nat Biotechnol; 2008 Jul; 26(7):724-5. PubMed ID: 18612282
    [No Abstract]   [Full Text] [Related]  

  • 12. Antiinfective biotechs face partnering gap.
    Sheridan C
    Nat Biotechnol; 2005 Feb; 23(2):155-6. PubMed ID: 15696131
    [No Abstract]   [Full Text] [Related]  

  • 13. Never again.
    Scott C
    Nat Biotechnol; 2010 Feb; 28(2):131. PubMed ID: 20139946
    [No Abstract]   [Full Text] [Related]  

  • 14. Advice for partnering with pharma.
    Howard K
    Nat Biotechnol; 2004 Nov; 22(11):1477-9. PubMed ID: 15586421
    [No Abstract]   [Full Text] [Related]  

  • 15. GSK moves on Sirtris.
    Sipp D
    Nat Biotechnol; 2008 Jun; 26(6):595. PubMed ID: 18536662
    [No Abstract]   [Full Text] [Related]  

  • 16. Exiting this year and into the next.
    Nat Biotechnol; 2005 Dec; 23(12):1451. PubMed ID: 16333272
    [No Abstract]   [Full Text] [Related]  

  • 17. Merv Turner.
    Turner M
    Nat Biotechnol; 2011 Mar; 29(3):186. PubMed ID: 21390005
    [No Abstract]   [Full Text] [Related]  

  • 18. Are the large pharmaceutical and biotechnology companies driving the discovery, research and development of targeted cancer therapies?
    Gallant GJ
    Future Med Chem; 2012 Jan; 4(1):13-7. PubMed ID: 22168161
    [No Abstract]   [Full Text] [Related]  

  • 19. Millennium ends Takeda's US shopping spree.
    Sipp D
    Nat Biotechnol; 2008 Jun; 26(6):593-5. PubMed ID: 18536661
    [No Abstract]   [Full Text] [Related]  

  • 20. Monoclonals expand into neural disorders.
    Vastag B
    Nat Biotechnol; 2006 Jun; 24(6):595-6. PubMed ID: 16763572
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.